|
|
(MedPage Today) -- SILVER SPRING, Md. -- An FDA advisory committee has voted 13-7 that the modest weight-loss benefits of an investigational combination of naltrexone and bupropion (Contrave) outweigh the drug's blood pressure risk.
Read from Source
|
| |
| |
| | 192 |
| |
|
|
|
|
|
|
